|
23 Apr 2008 |
Cytheris Announces New Phase I Study of Interleukin-7 As Immunotherapy In Treatment of Bone Marrow or Peripheral Blood Stem Cell Transplant Patients
|
|
23 Apr 2008 |
Stem Cell Therapeutics Corp. Receives "May Proceed" From FDA for Its Phase IIb Clinical Stroke Trial and IND
|
|
23 Apr 2008 |
Spectrum Pharmaceuticals Provides an Update on Ozarelix in BPH
|
|
22 Apr 2008 |
Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
|
|
22 Apr 2008 |
Eurand Announces EUR-1008 (Zentase) Eligibility for European Centralized Review
|
|
21 Apr 2008 |
Savient Provides Update On Puricase(R) (pegloticase) Biologics License Application
|
|
21 Apr 2008 |
Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
|
|
21 Apr 2008 |
Genzyme Provides Update on Myozyme(R) Manufacturing
|
|
19 Apr 2008 |
Aida Announces New Anti-Cancer Drug Under Development
|
|
18 Apr 2008 |
Lipid Sciences Presents HDL Mimetic Peptide Data at Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference
|
|
17 Apr 2008 |
12 Month Analysis of Juvista Clinical Trials 0050 and 0036
|
|
16 Apr 2008 |
Zelos Therapeutics and Aegis Therapeutics Announce Collaboration for Intranasal Delivery of Zelos’ ZT-031
|
|
16 Apr 2008 |
Teva Seeks Approval for the Extension of its Indication to Include the Treatment of Patients with a First Clinical Event Suggestive of MS
|
|
14 Apr 2008 |
Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
|
|
14 Apr 2008 |
TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanismof-Action at AACR Annual Meeting
|
|
14 Apr 2008 |
Debiopharm and Airmid Sign Option and License Agreement
|
|
10 Apr 2008 |
Copaxone® Significantly Reduced Annual Relapse Rates And Stabilized Disease Progression In Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment
|
|
09 Apr 2008 |
Pfizer Statement on Exubera Labeling Update in the United States
|
|
09 Apr 2008 |
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II StudyEvaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
|
|
09 Apr 2008 |
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
|
|
09 Apr 2008 |
Acorda Therapeutics Signs GGF2 Manufacturing Agreement with CMC ICOS
|
|
08 Apr 2008 |
Protox Initiates Phase 2 BPH Study
|
|
08 Apr 2008 |
WEX Starts Phase III Trial of Tectin(TM) for Cancer Pain
|
|
04 Apr 2008 |
FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
|
|
03 Apr 2008 |
Kamada Announces that it had Succesfully Met the Primary Endpoint in its US Phase III Clinical Trial with Intravenous AAT
|
